References
Key articles
World Health Organization. Typhoid vaccines position paper. Mar 2018 [internet publication].Full text
Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ. 2004 May;82(5):346-53.Full text Abstract
Schwartz E, Shlim DR, Eaton M, et al. The effect of oral and parenteral typhoid vaccination on the rate of infection with Salmonella typhi and Salmonella paratyphi A among foreigners in Nepal. Arch Intern Med. 1990 Feb;150(2):349-51. Abstract
Ochiai RL, Wang X, von Seidlein L, et al. Salmonella paratyphi A rates, Asia. Emerg Infect Dis. 2005 Nov;11(11):1764-6.Full text Abstract
Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 5: travel-associated infections & diseases - typhoid & paratyphoid fever. May 2023 [internet publication].Full text
Engels EA, Falagas ME, Lau J, et al. Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. BMJ. 1998 Jan 10;316(7125):110-6.Full text Abstract
Jackson BR, Iqbal S, Mahon B; Centers for Disease Control and Prevention (CDC). Updated recommendations for the use of typhoid vaccine - Advisory Committee on Immunization Practices, United States, 2015. MMWR Morb Mortal Wkly Rep. 2015 Mar 27;64(11):305-8.Full text Abstract
Frenck RW Jr, Nakhla I, Sultan Y, et al. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children. Clin Infect Dis. 2000 Nov;31(5):1134-8.Full text Abstract
Reference articles
1. World Health Organization. Typhoid vaccines position paper. Mar 2018 [internet publication].Full text
2. GBD 2017 Typhoid and Paratyphoid Collaborators. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis. 2019 Apr;19(4):369-81.Full text Abstract
3. DeRoeck D, Jodar L, Clemens J. Putting typhoid vaccination on the global health agenda. N Engl J Med. 2007 Sep 13;357(11):1069-71.Full text Abstract
4. Wain J, Hendriksen RS, Mikoleit ML, et al. Typhoid fever. Lancet. 2015 Mar 21;385(9973):1136-45. Abstract
5. Mermin JH, Townes JM, Gerber M, et al. Typhoid fever in the United States, 1985-1994: changing risks of international travel and increasing antimicrobial resistance. Arch Intern Med. 1998 Mar 23;158(6):633-8.Full text Abstract
6. Taylor DN, Pollard RA, Blake PA. Typhoid in the United States and the risk to the international traveler. J Infect Dis. 1983 Sep;148(3):599-602. Abstract
7. Ryan CA, Hargrett-Bean NT, Blake PA. Salmonella typhi infections in the United States, 1975-1984: increasing role of foreign travel. Rev Infect Dis. Jan-Feb 1989;11(1):1-8. Abstract
8. Meltzer E, Yossepowitch O, Sadik C, et al. Epidemiology and clinical aspects of enteric fever in Israel. Am J Trop Med Hyg. 2006 Apr;74(4):540-5.Full text Abstract
9. Lester A, Mygind O, Jensen KT, et al. Typhoid and paratyphoid fever in Denmark 1986-1990: epidemiologic aspects and the extent of bacteriological follow-up of patients. Ugeskr Laeger. 1994 Jun 20;156(25):3770-5. Abstract
10. Yew FS, Goh KT, Lim YS. Epidemiology of typhoid fever in Singapore. Epidemiol Infect. 1993 Feb;110(1):63-70.Full text Abstract
11. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ. 2004 May;82(5):346-53.Full text Abstract
12. Acharya IL, Lowe CU, Thapa R, et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med. 1987 Oct 29;317(18):1101-4. Abstract
13. Manesh A, Meltzer E, Jin C, et al. Typhoid and paratyphoid fever: a clinical seminar. J Travel Med. 2021 Apr 14;28(3):taab012.Full text Abstract
14. Meltzer E, Sadik C, Schwartz E. Enteric fever in Israeli travelers: a nationwide study. J Travel Med. Sep-Oct 2005;12(5):275-81.Full text Abstract
15. Caumes E, Ehya N, Nguyen J, et al. Typhoid and paratyphoid fever: a 10-year retrospective study of 41 cases in a Parisian hospital. J Travel Med. Nov-Dec 2001;8(6):293-7.Full text Abstract
16. Jelinek T, Nothdurft HD, von Sonnenburg F, et al. Risk factors for typhoid fever in travelers. J Travel Med. 1996 Dec 1;3(4):200-3.Full text Abstract
17. Angell SY, Cetron MS. Health disparities among travelers visiting friends and relatives abroad. Ann Intern Med. 2005 Jan 4;142(1):67-72.Full text Abstract
18. Boggild AK, Castelli F, Gautret P, et al. Vaccine preventable diseases in returned international travelers: results from the GeoSentinel Surveillance Network. Vaccine. 2010 Oct 28;28(46):7389-95. Abstract
19. Klemm EJ, Shakoor S, Page AJ, et al. Emergence of an extensively drug-resistant Salmonella enterica serovar typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins. mBio. 2018 Feb 20;9(1):e00105-18.Full text Abstract
20. Chatham-Stephens K, Medalla F, Hughes M, et al. Emergence of extensively drug-resistant Salmonella typhi infections among travelers to or from Pakistan - United States, 2016-2018. MMWR Morb Mortal Wkly Rep. 2019 Jan 11;68(1):11-3.Full text Abstract
21. François Watkins LK, Winstead A, Appiah GD, et al. Update on extensively drug-resistant Salmonella serotype typhi infections among travelers to or from Pakistan and report of ceftriaxone-resistant Salmonella serotype typhi infections among travelers to Iraq - United States, 2018-2019. MMWR Morb Mortal Wkly Rep. 2020 May 22;69(20):618-22.Full text Abstract
22. Engsbro AL, Riis Jespersen HS, Goldschmidt MI, et al. Ceftriaxone-resistant Salmonella enterica serotype typhi in a pregnant traveller returning from Karachi, Pakistan to Denmark, 2019. Euro Surveill. 2019 May;24(21):1900289.Full text Abstract
23. Wong W, Rawahi HA, Patel S, et al. The first Canadian pediatric case of extensively drug-resistant Salmonella typhi originating from an outbreak in Pakistan and its implication for empiric antimicrobial choices. IDCases. 2019 Jan 15;15:e00492.Full text Abstract
24. Hughes MJ, Birhane MG, Dorough L, et al. Extensively drug-resistant typhoid fever in the United States. Open Forum Infect Dis. 2021 Dec;8(12):ofab572.Full text Abstract
25. Safdar A, Kaur H, Elting L, et al. Antimicrobial susceptibility of 128 Salmonella enterica serovar typhi and paratyphi A isolates from northern India. Chemotherapy. 2004 Jun;50(2):88-91. Abstract
26. Goh YL, Yasin R, Puthucheary SD, et al. DNA fingerprinting of human isolates of Salmonella enterica serotype paratyphi B in Malaysia. J Appl Microbiol. 2003;95(5):1134-42.Full text Abstract
27. Ispahani P, Slack RC. Enteric fever and other extraintestinal salmonellosis in University Hospital, Nottingham, UK, between 1980 and 1997. Eur J Clin Microbiol Infect Dis. 2000 Sep;19(9):679-87. Abstract
28. Grewal HM, Jureen R, Steinsland H, et al. Molecular epidemiological study of Salmonella enterica serovar paratyphi B infections imported from Turkey to Western Norway. Scand J Infect Dis. 2002;34(1):5-10. Abstract
29. Oboegbulam SI, Oguike JU, Gugnani HC. Microbiological studies on cases diagnosed as typhoid/enteric fever in south-east Nigeria. J Commun Dis. 1995 Jun;27(2):97-100. Abstract
30. Kariuki S, Cheesbrough J, Mavridis AK, et al. Typing of Salmonella enterica serotype paratyphi C isolates from various countries by plasmid profiles and pulsed-field gel electrophoresis. J Clin Microbiol. 1999 Jun;37(6):2058-60.Full text Abstract
31. Schwartz E, Shlim DR, Eaton M, et al. The effect of oral and parenteral typhoid vaccination on the rate of infection with Salmonella typhi and Salmonella paratyphi A among foreigners in Nepal. Arch Intern Med. 1990 Feb;150(2):349-51. Abstract
32. Ochiai RL, Wang X, von Seidlein L, et al. Salmonella paratyphi A rates, Asia. Emerg Infect Dis. 2005 Nov;11(11):1764-6.Full text Abstract
33. Petersiel N, Shresta S, Tamrakar R, et al. The epidemiology of typhoid fever in the Dhulikhel area, Nepal: a prospective cohort study. PLoS One. 2018 Sep 27;13(9):e0204479.Full text Abstract
34. Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011 Dec;34(11-12):1269-81.Full text Abstract
35. Vollaard AM, Ali S, Widjaja S, et al. Identification of typhoid fever and paratyphoid fever cases at presentation in outpatient clinics in Jakarta, Indonesia. Trans R Soc Trop Med Hyg. 2005 Jun;99(6):440-50. Abstract
36. O'Brien D, Tobin S, Brown GV, et al. Fever in returned travelers: review of hospital admissions for a 3-year period. Clin Infect Dis. 2001 Sep 1;33(5):603-9.Full text Abstract
37. Steinberg EB, Bishop R, Haber P, et al. Typhoid fever in travelers: who should be targeted for prevention? Clin Infect Dis. 2004 Jul 15;39(2):186-91.Full text Abstract
38. Basnyat B, Qamar FN, Rupali P, et al. Enteric fever. BMJ. 2021 Feb 26;372:n437.Full text
39. Parry CM, Hien TT, Dougan G, et al. Typhoid fever. N Engl J Med. 2002 Nov 28;347(22):1770-82.Full text
40. Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 5: travel-associated infections & diseases - typhoid & paratyphoid fever. May 2023 [internet publication].Full text
41. Engels EA, Falagas ME, Lau J, et al. Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. BMJ. 1998 Jan 10;316(7125):110-6.Full text Abstract
42. Stubi CL, Landry PR, Petignat C, et al. Compliance to live oral Ty21a typhoid vaccine and its effect on viability. J Travel Med. May-Jun 2000;7(3):133-7.Full text Abstract
43. Cryz SJ. Patient compliance in the use of Vivotif Berna vaccine, typhoid vaccine, live oral Ty21a. J Travel Med. 1998 Mar;5(1):14-7.Full text Abstract
44. Klugman KP, Koornhof HJ, Robbins JB, et al. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine. 1996 Apr;14(5):435-8. Abstract
45. Khan MI, Soofi SB, Ochiai RL, et al; DOMI Typhoid Karachi Vi Effectiveness Study Group. Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan. Vaccine. 2012 Aug 3;30(36):5389-95. Abstract
46. Zhou WZ, Koo HW, Wang XY, et al. Revaccination with locally-produced vi typhoid polysaccharide vaccine among Chinese school-aged children: safety and immunogenicity findings. Pediatr Infect Dis J. 2007 Nov;26(11):1001-5. Abstract
47. Beeching NJ, Clarke PD, Kitchin NR, et al. Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults. Vaccine. 2004 Nov 15;23(1):29-35. Abstract
48. Lin FY, Vo AH, Khiem HB, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med. 2001 Apr 26;344(17):1263-9.Full text Abstract
49. Mai NL, Phan VB, Vo AH, et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Engl J Med. 2003 Oct 2;349(14):1390-1. Abstract
50. Milligan R, Paul M, Richardson M, et al. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev. 2018 May 31;(5):CD001261.Full text Abstract
51. Shakya M, Voysey M, Theiss-Nyland K, et al. Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial. Lancet Glob Health. 2021 Nov;9(11):e1561-8.Full text Abstract
52. Qadri F, Khanam F, Liu X, et al. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. Lancet. 2021 Aug 21;398(10301):675-84.Full text Abstract
53. Patel PD, Patel P, Liang Y, et al. Safety and efficacy of a typhoid conjugate vaccine in Malawian children. N Engl J Med. 2021 Sep 16;385(12):1104-15.Full text Abstract
54. Jin C, Gibani MM, Moore M, et al. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella typhi: a randomised controlled, phase 2b trial. Lancet. 2017 Dec 2;390(10111):2472-80.Full text Abstract
55. Jackson BR, Iqbal S, Mahon B; Centers for Disease Control and Prevention (CDC). Updated recommendations for the use of typhoid vaccine - Advisory Committee on Immunization Practices, United States, 2015. MMWR Morb Mortal Wkly Rep. 2015 Mar 27;64(11):305-8.Full text Abstract
56. Levine MM, Ferreccio C, Black RE, et al. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin Infect Dis. 2007 Jul 15;45(suppl 1):S24-8.Full text Abstract
57. Crump JA, Sjölund-Karlsson M, Gordon MA, et al. Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive Salmonella infections. Clin Microbiol Rev. 2015 Oct;28(4):901-37.Full text Abstract
58. Antillon M, Saad NJ, Baker S, et al. The relationship between blood sample volume and diagnostic sensitivity of blood culture for typhoid and paratyphoid fever: a systematic review and meta-analysis. J Infect Dis. 2018 Nov 10;218(suppl_4):S255-67.Full text Abstract
59. Bhutta ZA. Current concepts in the diagnosis and treatment of typhoid fever. BMJ. 2006 Jul 8;333(7558):78-82.Full text Abstract
60. Sánchez-Jiménez MM, Cardona-Castro N. Validation of a PCR for diagnosis of typhoid fever and salmonellosis by amplification of the hilA gene in clinical samples from Colombian patients. J Med Microbiol. 2004 Sep;53(Pt 9):875-8.Full text Abstract
61. Wain J, Diep TS, Ho VA, et al. Quantitation of bacteria in blood of typhoid fever patients and relationship between counts and clinical features, transmissibility, and antibiotic resistance. J Clin Microbiol. 1998 Jun;36(6):1683-7.Full text Abstract
62. Gilman RH, Terminel M, Levine MM, et al. Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella typhi in typhoid fever. Lancet. 1975 May 31;1(7918):1211-3. Abstract
63. Olopoenia LA, King AL. Widal agglutination test - 100 years later: still plagued by controversy. Postgrad Med J. 2000 Feb;76(892):80-4.Full text Abstract
64. Wijedoru L, Mallett S, Parry CM. Rapid diagnostic tests for typhoid and paratyphoid (enteric) fever. Cochrane Database Syst Rev. 2017 May 26;5(5):CD008892.Full text Abstract
65. Nabarro LE, McCann N, Herdman MT, et al. British infection association guidelines for the diagnosis and management of enteric fever in England. J Infect. 2022 Apr;84(4):469-89.Full text Abstract
66. Kuehn R, Stoesser N, Eyre D, et al. Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins. Cochrane Database Syst Rev. 2022 Nov 24;11(11):CD010452.Full text Abstract
67. Jin C, Gibani MM, Pennington SH, et al. Treatment responses to azithromycin and ciprofloxacin in uncomplicated Salmonella Typhi infection: a comparison of clinical and microbiological data from a controlled human infection model. PLoS Negl Trop Dis. 2019 Dec;13(12):e0007955.Full text Abstract
68. Cuypers WL, Jacobs J, Wong V, et al. Fluoroquinolone resistance in Salmonella: insights by whole-genome sequencing. Microb Genom. 2018 Jul;4(7):e000195.Full text Abstract
69. Pan American Health Organization/World Health Organization. Salmonella serovar Typhi haplotype H58 - epidemiological alert. Oct 2018 [internet publication].Full text
70. Parry CM, Qamar FN, Rijal S, et al. What should we be recommending for the treatment of enteric fever? Open Forum Infect Dis. 2023 May;10(suppl 1):S26-31.Full text Abstract
71. World Health Organizaion. The selection and use of essential medicines (2019) - TRS 1021. Jan 2020 [internet publication].Full text
72. Meltzer E, Stienlauf S, Leshem E, et al. A large outbreak of Salmonella paratyphi A infection among Israeli travelers to Nepal. Clin Infect Dis. 2014 Feb;58(3):359-64.Full text Abstract
73. Zmora N, Shrestha S, Neuberger A, et al. Open label comparative trial of mono versus dual antibiotic therapy for typhoid fever in adults. PLoS Negl Trop Dis. 2018 Apr;12(4):e0006380.Full text Abstract
74. Slinger R, Desjardins M, McCarthy AE, et al. Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series. BMC Infect Dis. 2004 Sep 20;4:36.Full text Abstract
75. Piersma D, Overbosch D, Petit P, et al. Protracted fever after a journey to India and Nepal: a case of persistent Salmonella paratyphi infection. J Travel Med. Jul-Aug 2004;11(4):257-9.Full text Abstract
76. US Food and Drug Administration. FDA drug safety communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Aug 2018 [internet publication].Full text
77. European Medicines Agency. Quinolone- and fluoroquinolone-containing medicinal products. Mar 2019 [internet publication].Full text
78. Frenck RW Jr, Nakhla I, Sultan Y, et al. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children. Clin Infect Dis. 2000 Nov;31(5):1134-8.Full text Abstract
79. Girgis NI, Butler T, Frenck RW, et al. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. Antimicrob Agents Chemother. 1999 Jun;43(6):1441-4.Full text Abstract
80. Chinh NT, Parry CM, Ly NT, et al. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. Antimicrob Agents Chemother. 2000 Jul;44(7):1855-9.Full text Abstract
81. Trivedi NA, Shah PC. A meta-analysis comparing the safety and efficacy of azithromycin over the alternate drugs used for treatment of uncomplicated enteric fever. J Postgrad Med. Apr-Jun 2012;58(2):112-8.Full text Abstract
82. Hoffman SL, Punjabi NH, Kumala S, et al. Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. N Engl J Med. 1984 Jan 12;310(2):82-8. Abstract
83. Cruz Espinoza LM, McCreedy E, Holm M, et al. Occurrence of typhoid fever complications and their relation to duration of illness preceding hospitalization: a systematic literature review and meta-analysis. Clin Infect Dis. 2019 Oct 30;69(suppl 6):S435-48.Full text Abstract
84. Public Health Agency of Canada. Canadian immunization guide: part 4 - active vaccines: typhoid vaccine. Sep 2016 [internet publication].Full text
85. Pieters Z, Saad NJ, Antillón M, et al. Case fatality rate of enteric fever in endemic countries: a systematic review and meta-analysis. Clin Infect Dis. 2018 Aug 1;67(4):628-38.Full text Abstract
87. Schwartz E, Jenks NP, Shlim DR. 'Typhoid hepatitis' or typhoid fever and acute viral hepatitis. Trans R Soc Trop Med Hyg. Jul-Aug 1994;88(4):437-8. Abstract
88. Chang YT, Lin JY, Huang YS. Typhoid colonic perforation in childhood: a ten-year experience. 2006. World J Surg. 2006 Feb;30(2):242-7. Abstract
89. Usang UE, Sowande OA, Ademuyiwa AO, et al. Outcome of primary closure of abdominal wounds following typhoid perforation in children in Ile-Ife, Nigeria. 2009. Afr J Paediatr Surg. Jan-Jun 2009;6(1):31-4.Full text Abstract
90. Ukwenya AY, Ahmed A, Garba ES. Progress in management of typhoid perforation. Ann Afr Med. 2011 Oct-Dec;10(4):259-65.Full text Abstract
91. Huang DB, DuPont HL. Problem pathogens: extra-intestinal complications of Salmonella enterica serotype Typhi infection. Lancet Infect Dis. 2005 Jun;5(6):341-8. Abstract
92. Biber A, Nof E, Schwartz E. Cardiac involvement in travelers with enteric fever. Am J Trop Med Hyg. 2019 May;100(5):1098-100.Full text Abstract
93. Mohanty S, Gaind R, Sehgal R, et al. Neonatal sepsis due to Salmonella typhi and paratyphi A. J Infect Dev Ctries. 2009 Sep 15;3(8):633-8.Full text Abstract
94. Edelman R, Levine MM. Summary of an international workshop on typhoid fever. Rev Infect Dis. May-Jun 1986;8(3):329-49. Abstract
Use of this content is subject to our disclaimer